Aldesleukin (high-dose IL-2)

Medicare

Part B (clinician-administered)

Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. High-dose IL-2 is given as an inpatient course, so hospital stays fall under Part A.

Commercial insurance

covered with prior authorisation

Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments.

20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.

Notes

Licensed for metastatic RCC since 1989; largely superseded and rarely used on the NHS. No TA.

NHS England

Routinely funded for the appraised indication (or via managed access)

Sources: NICE search: aldesleukin (high-dose IL-2). Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.